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ABSTRACT
Introduction: The efficacy of inhaled products
is affected by the degree, and potentially the
site, of drug particle deposition in the lungs.
Lung deposition correlates with the fine particle
fraction (FPF; the proportion of dose containing
particles \5 lm in aerodynamic diameter). This
in vitro study (defining fluticasone propionate/
formoterol particulate size [DIFFUSE])
examined the effects of inhalation flow rate on
the FPF of the fluticasone propionate/
formoterol (FP/FORM) pMDI aerosol compared
with three other inhaled corticosteroids/long-
acting b2-agonist (ICS/LABA) combination





Methods: Aerodynamic particle size
distribution was determined for each product
using an 8-stage Andersen Cascade Impactor at
two inhalation flow rates: 28.3 and 60.0 L/min.
Fine particle dose (mass of dose \5.0 lm) and
FPF were calculated as a percentage of the
labeled dose for the LABA and ICS of each
product at both flow rates.
Results: FP/FORM suspension aerosol provided
a high and consistent FPF of approximately 40%
for the ICS and LABA components at both flow
rates. At 28.3 L/min, the FPF of each component
of FP/FORM (41.2% and 39.2%) was greater
than that of FP/SAL DPI (12.5% and 11.3%),
BUD/FORM DPI (8.2% and 6.6%) and BDP/
FORM pMDI (28.5% and 26.0%). At 60.0 L/min,
the FPFs of the FP/FORM components (43.7%
and 42.1%) were greater than those of FP/SAL
(17.8% and 14.8%) and BUD/FORM (35.0% and
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30.1%), and similar to those of BDP/FORM
(43.0% and 39.5%).
Discussion: The FP/FORM suspension aerosol
produced a high and consistent FPF of
approximately 40% across both flow rates. The
consistent FPF in vitro may be predictive of FP/
FORM providing more consistent drug dosing
in vivo, helping to counteract variable lung
dose due to variation in inspiratory flow rate
among patients and between a patient’s day-to-
day or successive inhalation maneuvers.
Keywords: Aerodynamic particle size
distribution; Andersen Cascade Impactor;
Bronchodilators; Fine particle fraction; Flow
rate dependency; Inhaled corticosteroids/long-
acting b2-agonist combination products;
Pressurized metered-dose inhalers; Respiratory
INTRODUCTION
The efficacy of an inhaled drug is dependent on
the propensity for drug particles to deposit
throughout the lungs [1]. Deposition of drug
particles in the airways is affected by several,
often interrelated, factors, including the
intrinsic properties of the inhaler, drug
formulation and patient characteristics [2–5].
Drug formulation (i.e., dry powder or aerosol),
the mechanics of drug aerosolization and dose
delivery of the device [6], the particle carrier
and required inhalation rate for particle
deagglomeration [for dry-powder inhalers
(DPIs)] [7, 8], or the characteristics of the
propellant and the plume velocity [for
pressurized metered-dose inhalers (pMDIs)]
[4, 6, 9], as well as the particle size distribution
profile of the emitted drug, are all properties
inherent to the inhaled product. Patient-related
factors include anatomy, disease state, lung
function and the way in which an individual
uses his inhaler (i.e., device handling,
inhalation maneuvers, and inhalation flow
rate and volume) [1–3, 5, 10–12].
In vitro particle size profiles of emitted
particles correlate with in vivo lung deposition.
Particles larger than 5 lm in aerodynamic
diameter are prone to being deposited in the
mouth or throat, where they do not exert
therapeutic effects and may increase the risk of
local side effects [5, 13, 14]. Fine particles (\5 lm)
are associated with deposition throughout the
airways [1, 4, 5, 15–18]. The proportion of an
emitted aerosolized drug dose that contains fine
particles is referred to as the fine particle fraction
(FPF). Pharmacokinetic studies and three-
dimensional imaging techniques have shown
that inhaled corticosteroids (ICSs) with a higher
FPF are associated with greater levels of lung
deposition than those with a lower FPF [17, 19].
Imaging data have also indicated that fine
particles deposit in both the large and small
airways [19]. The FPF may therefore be an
important attribute for an ICS and long-acting
b2-agonist (LABA) combination therapy (ICS/
LABA) because the pathophysiology of asthma
involves both the proximal and distal airways.
The ICS targets inflammation, which affects
airways from the large bronchi to the alveoli,
while bronchodilation is driven by b2-agonists
acting on smooth muscle in the proximal airways
[19, 20]. Thus, it follows that the deposition
profile of an ICS/LABA combination therapy
should facilitate targeting of inflammation
throughout the lungs and provision of
bronchodilation in the proximal airways.
The ICS fluticasone propionate (FP) and LABA
formoterol fumarate (FORM) have been
combined in a single, hydrofluoroalkane (HFA)-
based, aerosol inhaler [FP/FORM; flutiform
(Jagotec AG, Muttenz, Switzerland)]. FP/FORM
has been approved for maintenance treatment of
asthma in adults and adolescents at twice-daily
doses of 100/10, 250/10 lg and (adults only)
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500/20 lg when an ICS/LABA therapy is
appropriate. The efficacy and tolerability of FP/
FORM across a range of asthma severities have
been demonstrated in several studies. FP/FORM
has a similar efficacy and tolerability profile to
those of fluticasone propionate/salmeterol
xinafoate (FP/SAL; pMDI) and budesonide/
formoterol (BUD/FORM; DPI), the two most
commonly prescribed ICS/LABA combinations
[21, 22].
It is widely accepted that DPIs are often
associated with flow rate-dependent changes in
the FPF; this is largely because the dry-powder
formulation needs to be deagglomerated into
respirable drug particles, a process that is
dependent, to a variable extent, on the
inspiratory force at which the patient inhales
through the device [7, 8, 23]. With pMDIs, drug
particles, either suspended or dissolved in a co-
solvent/propellant mixture (suspension or
solution formulations, respectively), are
aerosolized on actuation of the inhaler [6].
Therefore, it is expected that inhalation flow
rate would not have a significant impact on the
FPF. In this study (defining fluticasone
propionate/formoterol particulate size
[DIFFUSE]), the in vitro FPF profile of the FP/
FORM aerosol was compared with that of the
commercially available FP/SAL and BUD/FORM
DPIs. The beclometasone dipropionate
(beclometasone)/formoterol (BDP/FORM)




This study compared the aerodynamic particle
size distribution (APSD) profiles of FP/FORM
(pMDI) with three other single-inhaler ICS/
LABA combination products: FP/SAL [Seretide
Accuhaler (GlaxoOperations UK Ltd, Herts,
UK); DPI]; BUD/FORM [Symbicort
Turbohaler (AstraZeneca AB, So¨derta¨lje,
Sweden); DPI]; and BDP/FORM [Foster (Chiesi
Farmaceutici S.p.A, Parma, Italy); HFA pMDI].
Drug strengths were selected based on their
ability to deliver similar treatment doses
(Table 1).
Aerodynamic Particle Size Distribution
Profiles
APSD tests were performed using the Apparatus
D 8-stage Andersen Cascade Impactor (ACI;
Copley Scientific Limited, Nottingham, UK),
with an induction port and pre-separator for
powder formulations, according to the
European Pharmacopoeia 7.8, General
Chapter 2.9.18: ‘Preparations for inhalations,
aerodynamic assessment of fine particles’.
Testing was performed at room temperature
under ambient humidity conditions. To ensure
thermal re-equilibration of the valve, pMDIs
were actuated four times with a delay of
approximately 2 s between each actuation. For
the DPI testing, the plates of the ACI were
coated with a surfactant (Tween 20; Croda
France, Trappes Cedex, France) to avoid
potential bouncing or re-entrainment effects; a
pressure drop (4 kPa) was included at the start of
the ‘inhalation’, as recommended for quality
testing (to simulate the sharp initiation
inhalation recommended for DPIs). APSD
profiles were assessed at inhalation flow rates
of 28.3 and 60.0 L/min, which are within the
clinically effective range of flow rates for the
inhalers tested, and are consistent with industry
standards for the quality control testing of
inhaled medicines. Five inhalers were tested
for each product. The cumulative drug mass
recovered from the ACI following each test was
Comb Prod Ther (2013) 3:39–51 41
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normalized to the labeled dose for each
combination component at both flow rates
tested.
Fine Particle Fraction
The fine particle dose (mass of dose comprising
particles \5.0 lm) was interpolated from the
cumulative distribution for the ACI stages, with
cutoff diameters of 3.3, 4.7 and 5.8 lm, and
normalized for the labeled dose. The FPF was
calculated as a percentage of the labeled dose for
the ICS and for the LABA component of each
product, at both flow rates. The ratio between
FPFs at 60.0 and 28.3 L/min (FPF 60.0/28.3) for
both the ICS and LABA component of each ICS/
LABA combination tested was also calculated.
Median Mass Aerodynamic Diameter
The median mass aerodynamic diameter
(MMAD) was derived from inertial impaction
data, assuming a log-normal dispersion of sizes,
according to ISO 27427 ‘Anaesthetic and
respiratory equipment—nebulising systems
and components’. The geometric standard
deviation was calculated from the particle size
at the 84th percentile (by mass) divided by the
MMAD.
Statistical Analysis
The objectives of the study were: (1) to quantify
the effect of flow rate on the FPF for each of the
four products and (2) to compare the FPF of the
comparator products to that of the FP/FORM
pMDI at each of the studied flow rates. Results
from one inhaler (#3, Seretide batch R502221)
tested at 28.3 L/min were atypical and removed
from statistical analysis.
The FPF data were normalized to the target
metered dose to compare the products. Both
objectives were investigated by means of
standard equivalence testing; a 90%
confidence interval (CI) for the mean TEST/
REFERENCE ratio was determined based on log-
transformed FPF data, and equivalence was
concluded if the CI was contained in the
Table 1 Summary of the ICS/LABA combinations tested







Batch number AA11023 pMDI 125/5 250/10 2
FP/SALa
Batch number R502221 DPI 250/50 250/50 1
BUD/FORMb
Batch number NA3626 DPI 200/6 400/12 2
BDP/FORMc
Batch number 109215 pMDI 100/6 200/12 2
BDP beclometasone dipropionate, BUD budesonide, FP ﬂuticasone propionate, FORM formoterol fumarate, ICS inhaled
corticosteroid, LABA long-acting b2-agonist, pMDI pressurized metered-dose inhaler, SAL salmeterol xinafoate
a Seretide Accuhaler manufactured by Glaxo Operations UK Ltd, Hertfordshire, UK
b Symbicort Turbohaler manufactured by AstraZeneca AB, So¨derta¨lje, Sweden
c Foster manufactured by Chiesi Farmaceutici S.p.A., Parma, Italy
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0.85–1.18 (±15%) acceptance interval
recommended by the European Medicines
Agency for in vitro equivalence. For objective
(1) the reference was 60 L/min, and for objective
(2) the reference was FP/FORM. The same
analysis was performed independently for both
drug components. Means and standard
deviations are presented for each product; API
and flow rate were calculated in original scale
(not using the log transformation).
This article does not contain any studies of




FP/FORM produced a high FPF of approximately
40% for both the ICS and the LABA components
at flow rates of 28.3 and 60.0 L/min (Fig. 1). The
FPF of FP/FORM was significantly higher than
that of the FP/SAL and BUD/FORM DPIs
(Table 2; Fig. 1). The FP/SAL DPI produced an
FPF of less than 20% for each component at
both flow rates, while the FPF of budesonide for
the BUD/FORM DPI was 8.2% at 28.3 L/min and
35.0% at 60.0 L/min.
The FPF of FP/FORM was consistent across
the flow rates tested, as shown by the FPF 60.0/
28.3 ratios of 1.06 for fluticasone and 1.08 for
formoterol (Table 2), which were within the
specified acceptance interval for equivalence. By
contrast, the FPFs emitted from the FP/SAL and
BUD/FORM DPIs demonstrated marked flow
rate dependency. The FPF 60.0/28.3 ratio for
the FP/SAL DPI was 1.43 for fluticasone and 1.33
for salmeterol (Table 2). Similarly, the FPF of
BUD/FORM increased more than fourfold for
the ICS and LABA components between the
lower and higher flow rates (Fig. 1), with FPF
60.0/28.3 ratios of 4.38 for budesonide and 4.63
for formoterol (Table 2).
The FPF of BDP/FORM at 28.3 L/min was less
than 30%. The BDP/FORM FPF varied with flow
rate and was approximately 40% at 60.0 L/min
(Fig. 1; Table 2). The variation in the FPF across
flow rates was demonstrated by the 60.0/28.3
ratios of 1.51 for beclometasone and 1.52 for
formoterol (Table 2).
Aerodynamic Particle Size Distribution
Profiles and Median Mass Aerodynamic
Diameters
APSD profiles and MMADs were relatively
similar for the ICS and LABA components of
each combination tested, at both flow rates,
indicating consistency between component
particle size fractions (Table 3). FP/FORM
showed a similar cumulative particle fraction
distribution profile and MMAD at both 28.3 and
60.0 L/min, consistent with the similar FPFs
observed between flow rates (Fig. 2a; Table 3).
The APSD profile of FP/SAL was shallow at both
28.3 and 60.0 L/min, with particles distributed
across a broad range of sizes (Fig. 2b); there was
relative inconsistency in both the FPF and the
MMAD between the flow rates (Tables 2, 3). For
BUD/FORM, the APSD profile and MMAD were
both noticeably different at 28.3 L/min and at
60.0 L/min, with an increased mass of particles
in the range 1.1–10.0 lm at 60.0 L/min (Fig. 2c;
Table 3).
BDP/FORM also showed flow rate-dependent
effects for the cumulative particle fraction
(Fig. 2d), with a shift in the profile from 28.3
to 60.0 L/min and an increased mass of particles
smaller than 1.1 lm at the higher flow rate,
resulting in a decrease in the MMAD from
1.21 lm and 1.24 lm for ICS and LABA,
respectively, at 28.3 L/min, to 0.50 and
0.49 lm at 60.0 L/min (Table 3).
Comb Prod Ther (2013) 3:39–51 43
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DISCUSSION
The primary aim of this in vitro study was to
characterize the FPF of the FP/FORM inhalation
aerosol relative to those of the two most widely
prescribed ICS/LABA DPIs at two different
inhalation flow rates that are achievable by
patients using both DPI and pMDIs, and that
Fig. 1 FPFs of the a ICS and b LABA components of the
combination therapies at 28.3 and 60.0 L/min. Error bars
represent standard error. CI conﬁdence interval, FPF ﬁne
particle fraction, ICS inhaled corticosteroid, LABA long-
acting b2-agonist
44 Comb Prod Ther (2013) 3:39–51
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are considered to deliver clinically effective
doses for these device types. The BDP/FORM
aerosol was originally included as a benchmark
pMDI in this study. FP/FORM produced a high
(approximately 40%) and consistent FPF at 28.3
and 60.0 L/min, which was greater than the FPF
of FP/SAL and BUD/FORM. By contrast, the FPF
varied across flow rates for both DPIs. For the
FP/SAL DPI, there was a 5.3% absolute increase
(42% relative increase) in ICS FPF and a 3.5%
absolute increase (31% relative increase) in
LABA FPF when the flow rate increased from
28.3 to 60.0 L/min. For the BUD/FORM DPI, the
difference in FPF between flow rates was greater:
an absolute increase of 26.8% (327% relative
increase) in ICS FPF and a 23.5% absolute
increase (356% relative increase) in LABA FPF
were observed when the flow rate was increased
from 28.3 to 60.0 L/min. These findings are
consistent with those of previous in vitro
investigations [8, 23, 24] and are largely due to
the inspiratory force required to deagglomerate
and aerosolize the drug dose during inhalation
with a DPI. The similarity of the drug mass
ratios for each size fraction, for all products
tested, demonstrated that ICS and LABA
particles generated during the atomization
process are consistent in size or are co-
associated, and would therefore be expected to
co-deposit in the airways. This finding is in line
with those of previous studies [25].
Given that MMAD and FPF are interrelated,
it was unsurprising that the consistent FPF of
FP/FORM correlated with MMAD at both flow
rates. In contrast, both DPIs produced higher
MMADs at the lower flow rate, which also








28.3 L/min 60.0 L/min
ICS component
FP/FORM (FP) – – 1.06 (1.02, 1.10)
FP/SAL (FP) 0.30 (0.28, 0.32)* 0.41 (0.40, 0.41)* 1.43 (1.36, 1.51)
BUD/FORM (BUD) 0.20 (0.18, 0.22)* 0.80 (0.73, 0.86)* 4.38 (3.71, 5.04)
BDP/FORM (BDP) 0.69 (0.66, 0.73)* 0.98 (0.95, 1.02) 1.51 (1.47, 1.55)
LABA component
FP/FORM (FORM) – – 1.08 (1.04, 1.11)
FP/SAL (SAL) 0.29 (0.28, 0.31)* 0.35 (0.34, 0.37)* 1.33 (1.20, 1.45)
BUD/FORM (FORM) 0.17 (0.15, 0.19)* 0.71 (0.65, 0.78)* 4.63 (3.92, 5.33)
BDP/FORM (FORM) 0.66 (0.63, 0.70)* 0.94 (0.92, 0.96)* 1.52 (1.47, 1.57)
BDP beclometasone dipropionate, BUD budesonide, CI conﬁdence interval, FP ﬂuticasone propionate, FORM formoterol
fumarate, FPF ﬁne particle fraction, ICS inhaled corticosteroid, LABA long-acting b2-agonist, SAL salmeterol xinafoate
* Indicates statistical difference at the P\0.1 level versus FP/FORM
a Ratio (90% CI) of FPF versus FP/FORM
b Ratio (90% CI) of FPF at 28.3 versus 60 L/min
Comb Prod Ther (2013) 3:39–51 45
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varied considerably with increasing flow rate.
The FP/SAL DPI was associated with relatively
large particles (correlating with the flat APSD
profile), with an MMAD of 4.89 lm for the
LABA component at the lower flow rate. The
BUD/FORM DPI produced an MMAD of 3.77 lm
for the LABA component at the lower flow rate.
These data indicate that at the lower flow rate, a
large proportion of the dose of FP/SAL is
emitted as particles larger than 5 lm; particles
of this size are known to be more prone to being
deposited in the mouth and throat than fine
particles [5]. This increased risk of
oropharyngeal deposition may be associated
with local adverse effects [13, 14]. As expected,
the magnitude of the flow rate effect on MMAD
was greater for BUD/FORM than for FP/SAL,
with a shift in MMAD from approximately
3.8 lm (at 28.3 L/min) to approximately
2.5 lm (at 60.0 L/min) for both the LABA and
ICS components. These findings highlight that
there is greater potential for deposition of large
particles in the mouth and throat, rather than
in the airways, at a lower inhalation flow rate
for both DPIs compared with the pMDIs tested
in this study.
Data on the FPF for BDP/FORM have been
reported previously by Lewis and colleagues [25]
as a proportion of the delivered dose at a flow
rate of 28.3 L/min. In the present study, FPFs
were calculated as a proportion of the labeled
dose, and the FPF for the LABA component of
BDP/FORM was 26.0% at 28.3 L/min. When the
data reported by Lewis and colleagues were
recalculated as a proportion of the labeled dose,
rather than the delivered dose, the FPF for the
LABA component of BDP/FORM was 31.6%,
which is comparable to the finding of the
present study. In addition, the MMAD values
calculated in the present study for BDP/FORM
were similar to those reported by Lewis and
colleagues (1.21 lm for the ICS and 1.24 lm for
the LABA in the present study, versus 1.4 and
1.5 lm, respectively, as reported by Lewis). The
aerosolized drug emitted from a pMDI is
influenced by the propellant and the
characteristics of the inhaler and, unlike DPIs,
is not dependent on inspiratory force to
deagglomerate the drug. This can lead to the
perception that the FPF generated with pMDIs is
also not dependent on inhalation flow rate.
However, when flow rate increased from 28.3 to
60.0 L/min, there was an increase in the BDP/
FORM FPF (formoterol component, from 26.0%
to 39.5%). Similar to the findings for both DPIs,
the flow rate dependency of the BDP/FORM FPF
Table 3 MMADs for the ICS and LABA components of










FP/FORM (FP) 3.52 ± 1.59 3.15 ± 1.77
FP/SAL (FP) 4.65 ± 1.66 3.72 ± 1.83
BUD/FORM
(BUD)
3.77 ± 1.94 2.49 ± 1.91
BDP/FORM
(BDP)




3.52 ± 1.56 3.17 ± 1.71
FP/SAL (SAL) 4.89 ± 1.86 3.97 ± 1.96
BUD/FORM
(FORM)
3.77 ± 1.92 2.53 ± 1.89
BDP/FORM
(FORM)
1.24 ± 2.87 0.49 ± 5.33
BDP beclometasone dipropionate, BUD budesonide, FP
ﬂuticasone propionate, FORM formoterol fumarate, GSD,
geometric standard deviation; ICS inhaled corticosteroid,
LABA long-acting b2-agonist, MMAD median mass
aerodynamic diameter, SAL salmeterol xinafoate
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correlated with a lower MMAD at the 60.0 L/
min flow rate (from 1.21 lm at 28.3 L/min to
0.50 lm at 60.0 L/min for the ICS),
demonstrating the shift toward much smaller
particles with increasing flow rate.
The cause of the observed effect of flow rate
on BDP/FORM is not understood fully and we
are not aware of any published data reporting
the APSD profile of the BDP/FORM aerosol at
60.0 L/min or higher. Environmental and
experimental factors, such as humidity and
temperature, can influence aerosolized drug
characteristics in vitro [26]. All products tested
in the present study, however, were subject to
the same environmental and experimental
parameters, with only flow rate as a variable.
Given that both combinations were analyzed
under identical conditions and in accordance
with the European Pharmacopoeia
methodology, it is highly likely that the
observed results relate to an effect of flow rate.
There is support for this from a previous study,
which demonstrated that the in vitro
performance of some ICS/LABAs can be
affected by flow rate, leading to increased
deposition of particles in the ‘throat’ of the
apparatus at low flow rates [27]. Such variance
in FPF could be attributed to several factors,
including turbulence (created as the aerosol is
generated owing to the velocity difference of
Fig. 2 Aerodynamic particle size distribution proﬁles of
the LABA component for a FP/FORM, b FP/SAL,
c BUD/FORM and d BDP/FORM. Error bars represent
standard error. Cumulative drug masses recovered from the
ACI normalized for labeled dose are shown at 28.3 and
60.0 L/min. ACI Andersen Cascade Impactor, ICS inhaled
corticosteroid, LABA long-acting b2-agonist
Comb Prod Ther (2013) 3:39–51 47
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the impactor air flow and the aerosol plume)
and droplet particle evaporation, which result
in changes to particle deposition in the
impactor throat [28, 29]. Flow rate had little
effect on fluticasone/formoterol, but a greater
impact on beclometasone/formoterol; hence,
the observed flow rate-dependent effects
probably relate to differences in the
formulations of the two products. There are
several differences between the composition of
the FP/FORM and the BDP/FORM aerosols, and
their respective devices: FP/FORM is a
suspension containing the propellant,
apaflurane (HFA-227), whereas BDP/FORM is a
solution and contains the propellant norflurane
(HFA-134a). Furthermore, there are differences
in alcohol content (FP/FORM: 1 mg/actuation;
BDP/FORM: 7 mg/actuation) and other
excipients (FP/FORM: sodium cromoglycate;
BDP/FORM: hydrochloric acid). Interestingly, a
similar flow rate-dependent effect has been
noted for an HFA-based, solution formulation
of beclometasone, which has a similar alcohol
content to that of the BDP/FORM product
tested in this study (8.35 mg/actuation) [24, 27].
Although an optimal particle size for ICS/
LABA therapy has not yet been determined [30],
it is known that large particles ([5 lm) are more
prone to being deposited in the throat and
mouth, and that very small extra-fine particles
(0.1–1.0 lm; those that deposit via diffusion
and sedimentation) are prone to exhalation,
especially if the breath-hold is insufficient. The
observation that the BDP/FORM aerosol
generated an MMAD of approximately 0.50 lm
(for the ICS component) at a flow rate of 60.0 L/
min may therefore have in vivo implications,
because at the higher flow rate there may be
increased potential for particle exhalation;
however, particle size distribution around the
MMAD has a greater influence on drug
deposition throughout the lungs than any
specific MMAD value [1, 31]. Evidence suggests
that fine particles in the range 2–5 lm may be a
suitable size for distribution of an ICS/LABA
throughout the lungs [18]. Indeed, in vivo
imaging techniques have shown that particles
in this size range deposit in both the large and
small airways [19]. In asthma, the large and
small airways associated with
bronchoconstriction and inflammation must
be treated [18]. A significant proportion of the
emitted FP/FORM dose, at both 28.3 and 60.0 L/
min, falls in this size range (2–5 lm), which may
facilitate drug deposition throughout the
airways.
As with any in vitro investigation, caution
must be applied when translating findings to
the in vivo setting [1]; however, the European
Pharmacopoeia methodology used in this study
is well established and can be used to predict
the behavior of drug particles in the human
respiratory tract [1]. In addition to the
properties inherent to the inhaler and the
drug formulation, a patient’s inspiratory
maneuvers will also affect the potential for
deposition of the drug in the airways. Patients
often make errors when taking their ICS/LABA,
emphasizing the need for regular training and
inhaler-use assessments [32]. Furthermore, a
patient’s inhalation flow rate is not constant
during an inhalation maneuver and may vary
from breath to breath, and therefore from dose
to dose; the flow rate may also vary from
patient to patient [24, 33]. Inhalation flow
rate impacts significantly on total and regional
patterns of deposition of drug particles in the
airways [19]. Therefore, an ICS/LABA with a
relatively flow rate independent, consistent FPF
might facilitate more uniform dosing in the
lungs, compensating for variations in
inspiratory flow rates among patients, and
variations in patients’ day-to-day or successive
inhalation maneuvers.
48 Comb Prod Ther (2013) 3:39–51
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In 12-week, randomized clinical trials, FP/
FORM has a similar efficacy and tolerability
profile to FP/SAL pMDI (in patients C18 years
with 125/5 and 50/5 lg FP/FORM doses) and
BUD/FORM DPI (in patients C12 years with
125/5 lg FP/FORM dose) [21, 22]. Patients need
to demonstrate optimal inhalation maneuvers
and undergo repeated training to maintain their
inhaler technique for inclusion in such studies;
hence, it would be unlikely that a difference
between two inhalers would be observed. There
is, however, evidence to suggest that some
modern HFA-based pMDIs, which have greater
FPFs than current DPIs and the discontinued
chlorofluorocarbon (CFC)-based pMDIs, may
provide better control of asthma symptoms. A
recent retrospective, observational study
compared asthma outcomes in 3,134 patients
who were receiving FP/SAL, administered via
either a DPI or a pMDI. The findings of this study
demonstrated that in practice, patients using a
pMDI achieved better asthma control than those
using a DPI [34]. The authors suggested that
these results could reflect differences in FPF
between the pMDI and DPI formulations of FP/
SAL. Notably, the FPF of the FP/SAL DPI in the
present study is markedly lower than that
previously reported for the pMDI formulation
(30–33%, as percentage of the metered dose),
when assessed using an ACI without a spacer, as
per the present study [35, 36]. Similarly, an HFA-
based formulation of beclometasone provided
better asthma outcomes than a CFC-based
version in another observational study.
Improved asthma control with the HFA-based
formulation may be related to the higher FPF.
CONCLUSION
In conclusion, in vitro FP/FORM emits a high
and consistent FPF (approximately 40%) at
28.3 and 60.0 L/min. The FPF of FP/FORM
was less affected by changes in flow rate than
the other products tested. Consistent FPFs
may be associated with potential in vivo
benefits.
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